Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

被引：48
|
作者：
Li, Qiao [1 ]
Quan, Lina [1 ]
Lyu, Jiankun [1 ]
He, Zenghui [1 ]
Wang, Xia [1 ]
Meng, Jiajia [1 ]
Zhao, Zhenjiang [1 ]
Zhu, Lili [1 ]
Liu, Xiaofeng [1 ]
Li, Honglin [1 ]
机构：
[1] East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China
来源：
ONCOTARGET | 2016年 / 7卷 / 40期
基金：
中国国家自然科学基金;
关键词：
immunotherapy; human programmed death 1; peptide inhibitor; protein-protein interactions (PPIs); de novo peptide design; CANCER-IMMUNOTHERAPY; HOT-SPOTS; WEB SERVER; BINDING; LIGANDS; ENERGY; DETERMINANTS; SIMULATION; EXPRESSION; PREDICTION;
D O I：
10.18632/oncotarget.11274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Blocking the interaction of human programmed death 1 (hPD-1) and its ligand hPD-L1 has been a promising immunotherapy in cancer treatment. In this paper, using a computational de novo peptide design method, we designed several hPD-1 binding peptides. The most potent peptide Ar5Y_4 showed a KD value of 1.38 +/- 0.39 mu M, comparable to the binding affinity of the cognate hPD-L1. A Surface Plasmon Resonance (SPR) competitive binding assay result indicated that Ar5Y_4 could inhibit the interaction of hPD-1/hPD-L1. Moreover, Ar5Y_4 could restore the function of Jurkat T cells which had been suppressed by stimulated HCT116 cells. Peptides described in this paper provide promising biologic candidates for cancer immunotherapy or diagnostics.
引用
收藏
页码：64967 / 64976
页数：10
相关论文
共 50 条
  • [41] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Umran Kucukgoz Gulec
    Emine Kilic Bagir
    Semra Paydas
    Ahmet Baris Guzel
    Derya Gumurdulu
    Mehmet Ali Vardar
    Archives of Gynecology and Obstetrics, 2019, 300 : 377 - 382
  • [42] Discovery and pharmacological characterization of JNJ-63723283, an anti-programmed cell death protein-1 (PD-1) antibody that blocks PD-1 function
    Ferrante, Catherine
    DeAngelis, Nikki
    Powers, Gordon
    Sendecki, Jocelyn
    Millar, Hillary
    Mattson, Bethany
    Pizutti, Darlene
    Mayer, Christina Lourdes
    Wang, Weirong
    Brittingham, Raymond
    Wheeler, John
    Barone, Linda
    Nanjunda, Rupesh
    Lacy, Eilyn R.
    Wu, Sheng-Jiun
    Luo, Jinquan
    Zudaire, Enrique
    Packman, Kathryn
    Geist, Brian
    Trouba, Kevin
    Lorenzi, Matthew V.
    Verona, Raluca I.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [43] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1127 - 1127
  • [44] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 220 - 220
  • [45] Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 51 - 55
  • [46] mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1)
    Kamalinia, Golnaz
    Engel, Brian J.
    Srinivasamani, Anupallavi
    Grindel, Brian J.
    Ong, Justin N.
    Curran, Michael A.
    Takahashi, Terry T.
    Millward, Steven W.
    Roberts, Richard W.
    ACS CHEMICAL BIOLOGY, 2020, 15 (06) : 1630 - 1641
  • [47] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 300 (02) : 377 - 382
  • [48] The Role of Programmed Cell Death 1/Programmed Death Ligand 1 (PD-1/PD-L1) Axis in Sepsis-Induced Apoptosis
    Coman, Oana
    Grigorescu, Bianca-Liana
    Hutanu, Adina
    Bacarea, Anca
    Vasiesiu, Anca Meda
    Fodor, Raluca Stefania
    Stoica, Florin
    Azamfirei, Leonard
    MEDICINA-LITHUANIA, 2024, 60 (07):
  • [49] Relationship of programmed death 1 (PD-1) expression to the recurrence in gastric cancer
    Eto, Shohei
    Iwata, Takashi
    Yoshikawa, Kozo
    Higashijima, Jun
    Nakao, Toshihiro
    Nishi, Masaaki
    Takasu, Chie
    Shimada, Mitsuo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).
    Tsai, Katy K.
    Shoushtari, Alexander Noor
    Munhoz, Rodrigo Ramella
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick Alexander
    Johnson, Douglas Buckner
    Hwang, Jimmy
    Daud, Adil
    Sosman, Jeffrey Alan
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael Andrew
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    Algazi, Alain Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345